newsfilter
← Latest News
Business Wire·

Axcella Announces Program Reprioritization and Corporate Restructuring

Move Positions Company to Best Focus on Long COVID Program Axcella Therapeutics (NASDAQ:AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic